Just watched the weight loss drug earnings drama unfold and man, the contrast is stark. Eli Lilly is absolutely crushing it while Novo Nordisk is getting reality-checked hard.

Let's talk Lilly first. Q4 sales jumped 43%, earnings per share up 51%, net income rocketing 50%. This isn't just growth—it's the kind of explosive expansion that gets Wall Street excited. Mounjaro and Zepbound are printing money. Mounjaro alone hit $7.4 billion worldwide, up 110%, with US sales alone crossing $4 billion. Zepbound followed a similar playbook, climbing 122% to over $4 billion in the US market. And here's the kicker: even with prices dipping slightly, their gross margins stayed fat at 82.5%. Better product mix and improved production costs more than offset the lower prices. This is what profitable scaling looks like.

Now flip to Novo Nordisk. Sure, they invented the modern weight loss drug market—Ozempic changed everything. But that early-mover advantage? It's basically gone. They did score a win with FDA approval of the oral Wegovy pill, which is moving fast in the self-pay market with around 50,000 prescriptions already. But then came the guidance bomb: declining sales and profit expected for 2026, lower realized prices due to US health policy shifts, and patents expiring in some markets. The market didn't like that one bit.

What's wild is how the narrative has completely flipped. Novo may have invented the category, but Lilly looks like the company actually built to dominate it at scale. Their earnings show they've figured out the profitability equation better. Wall Street is clearly picking a winner here, and it's not the inventor anymore—it's the one executing better.

This is the kind of earnings cycle that reshapes sector dynamics. Worth watching closely if you're tracking pharma or these weight loss drug plays.